DETAILED ACTION
Claims 36-43 from the claim set filed 9/19/2025 are pending. Claims 1-35 are cancelled.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
A claim for benefit of a prior-filed application under 35 U.S.C. 119(a)-(f) or under 35
U.S.C. 120, 121, 365(a)-(c), 386 (a) or 386(c) has been made. The effective filing date of the
present application is 7/19/2022.
Information Disclosure Statement
The information disclosure statements (IDS) submitted on 8/20/2025, 7/14/2025, and 1/10/2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.
Claim Interpretation
The claims in this application are given their broadest reasonable interpretation using the plainest meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art.
In regards to claim 36, Examiner respectfully notes the claim language, as currently written states: “a second portion comprising a nucleic acid sequence of SEQ ID NO: 35, or a sequence at least about 95% identical thereto.” In regards to dependent claim 37, Examiner respectfully notes the claim language, as currently written states: “wherein the second portion comprises a nucleic acid sequence of SEQ ID NO: 35.”
The Office interprets claims comprising SEQ ID NOs: in the following manner:
“comprising a sequence of SEQ ID NO: 1” requires, for example, only a 2mer of SEQ ID NO: 1;
“comprising the sequence of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 with any N-/C-terminal additions or any 5' /3' additions, i.e., the sequence does not need to be the exact length;
(C) “consisting of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 and the same length as SEQ ID NO: 1, i.e., nothing to the left or the right of the sequence; and
(d) “selected from the group consisting of SEQ ID NOs: 1, 2, and 3” requires the full-length sequence with 100% identity to SEQ ID NOs: 1, 2, or 3 and the same length as SEQ ID NOs: 1, 2, or 3.
Thus, the claim language as currently written, in regards to claim 36, i.e., “a second portion comprising a nucleic acid sequence of SEQ ID NO: 35, or a sequence at least about 95% identical thereto” reads on, for example, only a 2mer of SEQ ID NO: 35. Additionally, the claim language as currently written, in regards to claim 37, i.e., “wherein the second portion comprises a nucleic acid sequence of SEQ ID NO: 35” reads on, for example, only a 2mer of SEQ ID NO: 35. Thus, if the claims are read in this manner, claim 37 is not further limiting of claim 36. Thus, Examiner does not believe Applicant intends for the claims to be interpreted in this manner.
As such, Examiner is interpreting the language of claim 36 (and dependent claim 37) to be written as: “a second portion comprising the nucleic acid sequence of SEQ ID NO: 35, or a sequence at least about 95% identical thereto” (i.e., claim 36) and “wherein the second portion comprises the nucleic acid sequence of SEQ ID NO: 35” (i.e., claim 37).
The same interpretation is being applied to independent claims 38, 40, and 42 as well as to dependent claims 39, 41, and 43. I.e., the point (ii) claim language in independent claims 38, 40, and 42 is being interpreted as “a second portion comprising the nucleic acid sequence of SEQ ID NO: (60 [claim 38], or 62 [claim 40], or 71 [claim 42]), or a sequence at least about 95% identical thereto”. I.e., the claim language in dependent claims 39, 41, and 43 is being interpreted as “wherein the second portion comprises the nucleic acid sequence of SEQ ID NO: (60 [claim 39], or 62 [claim 41], or 71 [claim 43])”.
Claim Rejections - 35 USC § 112(d)
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claims 37, 39, 41, and 43 are rejected under 35 U.S.C. 112(d), 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Claims 37, 39, 41, and 43 depend from claims 36 (i.e., claim 37), 38 (i.e., claim 39), 40 (i.e., claim 41), and 42 (i.e., claim 43). As noted supra in the claim interpretation, the independent claim language (i.e., claims 36, 38, 40, and 42) is written in such a manner, i.e., “comprising a nucleic acid sequence” as to be interpreted as requiring only, for example, a 2mer of the nucleic acid sequence. Additionally, and as noted supra in the claim interpretation, the dependent claim language (i.e., claims 37, 39, 41, and 43) is written in such a manner, i.e., “comprises a nucleic acid sequence” as to be interpreted as requiring only, for example, a 2mer of the nucleic acid sequence. Thus, the dependent claims are not further limiting of the independent claims.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Double Patenting
Claims 36-43 are rejected on the grounds of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 12473567 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-27 of the reference application anticipate claims 36-43 of the instant application.
INSTANT APPLICATION
CLAIMS:
36. (New) An isolated, circular, non-viral, non-integrating DNA vector comprising:
(i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and
(ii) a second portion comprising a nucleic acid sequence of SEQ ID NO: 35, or a sequence at least about 95% identical thereto.
37. (New) The DNA vector of claim 36, wherein the second portion comprises a nucleic acid sequence of SEQ ID NO: 35.
38. (New) An isolated, circular, non-viral, non-integrating DNA vector comprising:(i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and(ii) a second portion comprising a nucleic acid sequence of SEQ ID NO: 60, or a sequence at least about 95% identical thereto.
39. (New) The DNA vector of claim 38, wherein the second portion comprises a nucleic acid sequence of SEQ ID NO. 60.
40. (New) An isolated, circular, non-viral, non-integrating DNA vector comprising:(i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and(ii) a second portion comprising a nucleic acid sequence of SEQ ID NO: 62, or a sequence at least about 95% identical thereto.
41. (New) The DNA vector of claim 40, wherein the second portion comprises a nucleic acid sequence of SEQ ID NO. 62.
42. (New) An isolated, circular, non-viral, non-integrating DNA vector comprising:(i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and(ii) a second portion comprising a nucleic acid sequence of SEQ ID NO: 71, or a sequence at least about 95% identical thereto.
43. (New) The DNA vector of claim 42, wherein the second portion comprises a nucleic acid sequence of SEQ ID NO. 71.
REFERENCE APPLICATION:
CLAIMS:
1. An isolated, circular, non-viral, non-integrating DNA vector comprising:
a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and
a second portion comprising a nucleic acid sequence consisting essentially of a first adeno-associated virus (AAV) inverted repeat sequence, an R6Kγ bacterial origin of replication (oriR6Kγ) sequence, and a second AAV inverted repeat sequence;
wherein the first AAV inverted repeat sequence, oriR6Kγ sequence, and second AAV inverted repeat sequence are contiguous, and wherein the oriR6Kγ sequence is flanked by, and in between, the first AAV inverted repeat sequence and the second AAV inverted repeat sequence.
2. The DNA vector of claim 1, wherein the oriR6Kγ sequence comprises a nucleic acid sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59.
3. The DNA vector of claim 2, wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59.
4. The DNA vector of claim 1, wherein each of the AAV inverted repeat sequences is independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-18.
5. The DNA vector of claim 4, wherein each of the AAV inverted repeat sequences is independently selected from the group consisting of SEQ ID NOS: 1-18.
6. The DNA vector of claim 1, wherein the first AAV inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17; wherein the oriR6Kγ sequence comprises a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59; and wherein the second AAV inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
7. The DNA vector of claim 6, wherein the first AAV inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17; wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59; and wherein the second AAV inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
8. The DNA vector of claim 1, wherein the second portion comprises a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 35, 60, 62, and 71.
9. The DNA vector of claim 8, wherein the second portion comprises a sequence selected from the group consisting of SEQ ID NOS: 35, 60, 62, and 71.
10. An isolated, circular, non-viral, non-integrating DNA vector comprising: (i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and (ii) a second portion comprising a nucleic acid sequence comprising the Formula X—Y—X′; wherein X and X′ are each separately an AAV inverted repeat sequence and Y consists essentially of an oriR6Kγ sequence.
11. The DNA vector of claim 10, wherein the oriR6Kγ sequence comprises a nucleic acid sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59.
12. The DNA vector of claim 11, wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59.
13. The DNA vector of claim 10, wherein X and X′ are independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-18.
14. The DNA vector of claim 13, wherein X and X′ are independently selected from the group consisting of SEQ ID NOS: 1-18.
15. The DNA vector of claim 10, wherein X is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17; wherein the oriR6Kγ sequence comprises a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59; and wherein X′ is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
16. The DNA vector of claim 15, wherein X is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17; wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59; and wherein X′ is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
17. The DNA vector of claim 10, wherein the second portion comprises a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 35, 60, 62, and 71.
18. The DNA vector of claim 17, wherein the second portion comprises a sequence selected from the group consisting of SEQ ID NOS: 35, 60, 62, and 71.
19. An isolated, circular, non-viral, non-integrating DNA vector comprising: (i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and (ii) a second portion comprising a nucleic acid sequence consisting essentially of, operably linked in a 5′ to a 3′ direction: (a) a first AAV inverted repeat sequence; (b) an oriR6Kγ sequence; and (c) a second AAV inverted repeat sequence.
20. The DNA vector of claim 19, wherein the oriR6Kγ sequence comprises a nucleic acid sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59.
21. The DNA vector of claim 20, wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59.
22. The DNA vector of claim 19, wherein each of the AAV inverted repeat sequences is independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-18.
23. The DNA vector of claim 22, wherein each of the AAV inverted repeat sequences is independently selected from the group consisting of SEQ ID NOS: 1-18.
24. The DNA vector of claim 19, wherein the first AAV inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17; wherein the oriR6Kγ sequence comprises a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59; and wherein the second AAV inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
25. The DNA vector of claim 24, wherein the first AAV inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17; wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58 and SEQ ID NO: 59; and wherein the second AAV inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
26. The DNA vector of claim 19, wherein the second portion comprises a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 35, 60, 62, and 71.
27. The DNA vector of claim 26, wherein the second portion comprises a sequence selected from the group consisting of SEQ ID NOS: 35, 60, 62, and 71.
The reference application claims anticipate the instant application as is shown below via sequence alignments.
Examiner respectfully notes the sequences of the reference application are identical to the sequences of the instant application. Thus, for example, SEQ ID NOs: 1, 58, and 2 of the reference application are identical to said sequences from the instant application. Additionally, for example, SEQ ID NOs: 35, 60, 62, and 71 of the reference application are identical to said sequences from the instant application.
The instant application is claiming a more concisely written form of the reference application, but in essence, both applications are claiming the same material.
As an example, Examiner is including below the sequence alignments of the instant application SEQ ID NO: 35 with the reference application SEQ ID NOs: 1, 58, and 2.
SEQ ID NO: 35 (IA) with SEQ ID NO: 1 (RA):
PNG
media_image1.png
317
652
media_image1.png
Greyscale
SEQ ID NO: 35 (IA) with SEQ ID NO: 58 (RA):
PNG
media_image2.png
501
665
media_image2.png
Greyscale
SEQ ID NO: 35 (IA) with SEQ ID NO: 2 (‘511):
PNG
media_image3.png
321
642
media_image3.png
Greyscale
In Summary, SEQ ID NO: 35 (IA) comprises, in order: SEQ ID NOs: 1, 58, and 2 of the RA.
For conciseness, Examiner is not including all sequence alignments.
Therefore, claims 1-27 of the reference application anticipate claims 36-43 of the instant application.
Claims 36-43 are rejected on the grounds of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 12473568 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-27 of the reference application anticipate claims 36-43 of the instant application.
REFERENCE APPLICATION:
Claims
1. A pharmaceutical composition for administration to a human comprising: (i) a circular, non-viral, non-integrating DNA vector comprising: (a) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and (b) a second portion comprising a nucleic acid sequence comprising a first inverted repeat sequence, a bacterial origin of replication (Ori) sequence, and a second inverted repeat sequence; wherein the first inverted repeat sequence, bacterial Ori sequence, and second inverted repeat sequence are contiguous, and wherein the Ori sequence is flanked by, and in between, the first inverted repeat sequence and the second inverted repeat sequence; and (ii) a lipid nanoparticle.
2. The pharmaceutical composition of claim 1, wherein the Ori sequence is derived from R6K.
3. The pharmaceutical composition of claim 1, wherein the Ori sequence is derived from an oriR6Kγ sequence.
4. The pharmaceutical composition of claim 3, wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 59, a nucleic acid sequence at least 90% identical to SEQ ID NO: 58, and a nucleic acid sequence at least 90% identical to SEQ ID NO: 59.
5. The pharmaceutical composition of claim 1, wherein the first inverted repeat sequence and second inverted repeat sequence are derived from an inverted repeat sequence from an adeno-associated virus (AAV).
6. The pharmaceutical composition of claim 5, wherein each of the inverted repeat sequences is independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-18.
7. The pharmaceutical composition of claim 6, wherein each of the inverted repeat sequences is independently selected from the group consisting of SEQ ID NOS: 1-18.
8. The pharmaceutical composition of claim 1, wherein the first inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein the second inverted repeat is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
9. The pharmaceutical composition of claim 8, wherein the first inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein the second inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
10. A pharmaceutical composition for administration to a human comprising: (i) a circular, non-viral, non-integrating DNA vector comprising: (a) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and (b) a second portion comprising a nucleic acid sequence capable of forming a cruciform structure, wherein the nucleic acid sequence capable of forming a cruciform structure comprises the Formula X—Y—X′; wherein X and X′ are each inverted repeat sequences and Y is a bacterial Ori sequence; and (ii) a lipid nanoparticle.
11. The pharmaceutical composition of claim 10, wherein the Ori sequence is derived from R6K.
12. The pharmaceutical composition of claim 10, wherein the Ori sequence is derived from an oriR6Kγ sequence.
13. The pharmaceutical composition of claim 12, wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 59, a nucleic acid sequence at least 90% identical to SEQ ID NO: 58, and a nucleic acid sequence at least 90% identical to SEQ ID NO: 59.
14. The pharmaceutical composition of claim 10, wherein X and X′ are derived from an inverted repeat sequence from an AAV.
15. The pharmaceutical composition of claim 14, wherein X and X′ are independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-18.
16. The pharmaceutical composition of claim 15, wherein X and X′ are independently selected from the group consisting of SEQ ID NOS: 1-18.
17. The pharmaceutical composition of claim 10, wherein X is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein X′ is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
18. The pharmaceutical composition of claim 17, wherein X is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein X′ is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
19. A pharmaceutical composition for administration to a human comprising: (i) a circular, non-viral, non-integrating DNA vector comprising: (a) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and (b) a second portion comprising a nucleic acid sequence capable of forming a cruciform structure, wherein the nucleic acid sequence capable of forming a cruciform structure consists essentially of, operably linked in a 5′ to a 3′ direction: (I) a first inverted repeat sequence; (II) a bacterial Ori; and (III) a second inverted repeat sequence; and (ii) a lipid nanoparticle.
20. The pharmaceutical composition of claim 19, wherein the Ori is derived from R6K.
21. The pharmaceutical composition of claim 19, wherein the Ori is derived from an oriR6Kγ sequence .
22. The pharmaceutical composition of claim 21, wherein the oriR6Kγ sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 59, a nucleic acid sequence at least 90% identical to SEQ ID NO: 58, and a nucleic acid sequence at least 90% identical to SEQ ID NO: 59.
23. The pharmaceutical composition of claim 19, wherein each of the inverted repeat sequences is derived from an inverted repeat sequence from an AAV.
24. The pharmaceutical composition of claim 23, wherein each of the inverted repeat sequences is independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-18.
25. The pharmaceutical composition of claim 24, wherein each of the inverted repeat sequences is independently selected from the group consisting of SEQ ID NOS: 1-18.
26. The pharmaceutical composition of claim 19, wherein the first inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein the second inverted repeat is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
27. The pharmaceutical composition of claim 26, wherein the first inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein the second inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
The reference application claims anticipate the instant application.
Examiner respectfully notes the sequences of the reference application are identical to the sequences of the instant application. Thus, for example, SEQ ID NOs: 1, 58, and 2 of the reference application are identical to said sequences from the instant application.
The instant application is claiming a more concisely written form of the reference application, but in essence, both applications are claiming the same vector. As shown below in the sequence alignments, instant application SEQ ID NO: 35 aligns with SEQ ID NOs: 1, 58, and 2.
As an example, Examiner is including below the sequence alignments of the instant application SEQ ID NO: 35 with the reference application SEQ ID NOs: 1, 58, and 2.
SEQ ID NO: 35 (IA) with SEQ ID NO: 1 (RA):
PNG
media_image1.png
317
652
media_image1.png
Greyscale
SEQ ID NO: 35 (IA) with SEQ ID NO: 58 (RA):
PNG
media_image2.png
501
665
media_image2.png
Greyscale
SEQ ID NO: 35 (IA) with SEQ ID NO: 2 (‘511):
PNG
media_image3.png
321
642
media_image3.png
Greyscale
In Summary, SEQ ID NO: 35 (IA) comprises, in order: SEQ ID NOs: 1, 58, and 2 of the RA.
For conciseness, Examiner is not including all sequence alignments.
Therefore, claims 1-27 of the reference application anticipate claims 36-43 of the instant application.
Claims 36-43 are provisionally rejected on the grounds of nonstatutory double patenting as being unpatentable over claims 55-79 of copending Application 19/015,381 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claims 55-79 of the reference application anticipate claims 36-43 of the instant application.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
REFERENCE APPLICATION
CLAIMS:
55. (New) An isolated, circular, non-viral, non-integrating DNA vector comprising:(i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and(ii) a second portion comprising a nucleic acid sequence consisting essentially of a first inverted repeat sequence, a bacterial origin of replication (Ori) sequence, and a second inverted repeat sequence; and wherein the first inverted repeat sequence, bacterial Ori sequence, and second inverted repeat sequence are contiguous, and wherein the Ori sequence is flanked by, and in between, the first inverted repeat sequence and the second inverted repeat sequence.
56. (New) The DNA vector of claim 55, wherein the Ori sequence is derived from R6K.
57. (New) The DNA vector of claim 55, wherein the Ori sequence is derived from an oriR6KT sequence.
58. (New) The DNA vector of claim 57, wherein the oriR6KT sequence comprises a nucleic acid sequence selected from SEQ TD NO: 58 or SEQ TD NO: 59, or a nucleic acid sequence at least 900% identical thereto.
59. (New) The DNA vector of claim 55, wherein the first inverted repeat sequence and second inverted repeat sequence are derived from an inverted repeat sequence from an adeno- associated virus (AAV).
60. (New) The DNA vector of claim 59, wherein the first inverted repeat sequence and second inverted repeat sequence are independently at least 900% identical to a sequence selected from the group consisting of SEQ ID NOS: 1 - 18.
61. (New) The DNA vector of claim 60, wherein the first inverted repeat sequence and second inverted repeat sequence are independently selected from a sequence of the group consisting of SEQ TD NOS: 1 - 18.
62. (New) The DNA vector of claim 58, wherein the first inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein the second inverted repeat is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and18.
63. (New) The DNA vector of claim 62, wherein the first inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein the second inverted repeat sequence is selected from the group consisting of SEQ ID NOS:2,4,6,8, 10, 12, 14, 16, and 18.
64. (New) An isolated, circular, non-viral, non-integrating DNA vector comprising:(i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and(ii) a second portion comprising a nucleic acid sequence comprising the Formula X- Y-X';wherein X and X' are each inverted repeat sequences and Y consists essentially of a bacterial Ori sequence.
65. (New) The DNA vector of claim 64, wherein the Ori sequence is derived from R6K.
66. (New) The DNA vector of claim 64, wherein the Ori sequence is derived from oriR6K7.
67. (New) The DNA vector of claim 66, wherein the oriR6K7 sequence comprises a nucleic acid sequence selected from SEQ ID NO: 58 or SEQ ID NO: 59, or a nucleic acid sequence at least 90% identical thereto.
68. (New) The DNA vector of claim 64, wherein X and X' are derived from an inverted repeat sequence from an AAV.
69. (New) The DNA vector of claim 68, wherein X and X' are independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1 - 18.
70. (New) The DNA vector of claim 69, wherein X and X' are independently a sequence selected from the group consisting of SEQ ID NOS: 1 - 18.
71. (New) The DNA vector of claim 67, wherein X is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein X' is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
72. (New) The DNA vector of claim 71, wherein X is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein X' is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
73. (New) An isolated, circular, non-viral, non-integrating DNA vector comprising:(i) a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and(ii) a second portion comprising a nucleic acid sequence consisting essentially of,operably linked in a 5' to a 3' direction:(a) a first inverted repeat sequence;(b) a bacterial Ori sequence; and(c) a second inverted repeat sequence.
74. (New) The DNA vector of claim 73, wherein the Ori sequence is derived from R6K.
75. (New) The DNA vector of claim 73, wherein the Ori sequence is derived from oriR6K7.
76. (New) The DNA vector of claim 75, wherein the oriR6K7 sequence comprises a nucleic acid sequence selected from SEQ ID NO: 58 or SEQ ID NO: 59, or a nucleic acid sequence at least 90% identical thereto.
77. (New) The DNA vector of claim 73, wherein each of the inverted repeat sequences is derived from an inverted repeat sequence from an AAV.
78. (New) The DNA vector of claim 77, wherein each of the inverted repeat sequences is independently at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1 - 18.
79. (New) The DNA vector of claim 78, wherein each of the inverted repeat sequences is independently selected from the group consisting of SEQ ID NOS: 1 - 18.
80. (New) The DNA vector of claim 76, wherein the first inverted repeat sequence is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7,
9, 11, 13, 15, and 17, and wherein the second inverted repeat is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18. 81. (New) The DNA vector of claim 80, wherein the first inverted repeat sequence is selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and wherein the second inverted repeat sequence is selected from the group consisting of SEQ ID NOS:
2,4,6,8, 10, 12, 14, 16, and 18.
The reference application claims anticipate the instant application.
Examiner respectfully notes the sequences of the reference application are identical to the sequences of the instant application. Thus, for example, SEQ ID NOs: 1, 58, and 2 of the reference application are identical to said sequences from the instant application.
The instant application is claiming a more concisely written form of the reference application, but in essence, both applications are claiming the same vector. For conciseness, Examiner is not including the sequence alignments, but, after performing a sequence alignment, Examiner found the instant application SEQ ID NO: 35 aligns with SEQ ID NOs: 1, 58, and 2 of the reference application. (I.e., the sequence alignments are identical to what is shown above in regards to the other reference applications.)
In Summary, SEQ ID NO: 35 (IA) comprises, in order: SEQ ID NOs: 1, 58, and 2 of the RA.
Therefore, claims 55-79 of the reference application anticipate claims 36-43 of the instant application.
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
ALLOWABLE SUBJECT MATTER
Examiner notes that after a thorough SEQ ID search, no prior art was found to anticipate or make obvious the instant claimed SEQ ID NOs: 35, 60, 62 and 71.
The instant application is related to application 19/060,511 (now Patent No. 12473567).
Claim 1 of ‘511 states:
An isolated, circular, non-viral, non-integrating DNA vector comprising:
a first portion comprising an expression cassette comprising a nucleic acid sequence encoding a therapeutic protein, wherein the nucleic acid sequence encoding the therapeutic protein is operably linked to a promoter; and
a second portion comprising a nucleic acid sequence consisting essentially of a first adeno-associated virus (AAV) inverted repeat sequence, an R6Kγ bacterial origin of replication (oriR6Kγ) sequence, and a second AAV inverted repeat sequence;
wherein the first AAV inverted repeat sequence, oriR6Kγ sequence, and second AAV inverted repeat sequence are contiguous, and wherein the oriR6Kγ sequence is flanked by, and in between, the first AAV inverted repeat sequence and the second AAV inverted repeat sequence.
Claim 8 of ‘511 states:
The DNA vector of claim 1, wherein the second portion comprises a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 35, 60, 62, and 71.
As found during the above noted SEQ ID search, SEQ ID NOs: 35, 60, 62, and 71 are 100% identical between ‘511 and the instant application. The sequence alignment for SEQ ID NO: 35 is included below as an example.
SEQ ID NO: 35 (IA) : SEQ ID NO: 35 (‘511)
PNG
media_image4.png
994
661
media_image4.png
Greyscale
As noted supra, ‘511 is now an issued patent (claiming as dependent claims the claimed SEQ ID NOs claimed in independent claims 36, 38, 40, and 42 in the instant application). Further, and as noted in the non-final rejection filed 8/6/2025 in regards to ‘511, the closest prior art is Williams (U.S. Patent Application Publication No. 2021/0010021, published January 14, 2021; IDS filed 1/10/2025) in view of Harbottle (PG Pub No. WO 2019/057774 A1; IDS filed 8/20/2025). As noted in the NOA filed 9/6/2025 in regards to ‘511:
Applicant alleges that Williams does not describe the specific orientation of the DNA vector of the present claims because the vector of Williams further includes an RNA-Out selection marker sequence flanking the bacterial origin of replication (Remarks; pg. 7, lines 10).
As noted in said NOA, this argument is found to be persuasive because neither Williams nor the prior art teaches the use of a DNA vector comprising the claimed structure, wherein the vector does not comprise an RNA-Out selection marker located between the claimed ITRs.
Application alleges that the named inventors of the present application have discovered the unexpected results that the inclusion of an RNA-Out functional sequence element flanking and contiguous with the bacterial origin of replication exhibit lover levels of transgene expression over time when compared to the instantly claimed vector comprising a first AAV ITR, an oriR6Kγ, and a second AAV ITR, wherein the oriR6Kγ is flanked by, and in between, the first and second AAV ITRs (Remarks; pg. 8, lines 1-15).
As noted in said NOA, this argument is found persuasive because neither Williams, Harbottle, nor the prior art teaches or suggests the unexpected result demonstrated by Applicant.
Applicant alleges that while Harbottle does teach the use of R6K Ori sequences in non-viral, non-integrating DNA expression vectors, the R6Kori sequences of Harbottle are in tandem with a selectable marker (Remarks; pg. 9, lines 1-25).
As noted in said NOA, this argument is found persuasive because neither Harbottle nor the prior art teaches the use of a DNA vector comprising the claimed structure, wherein the vector does not comprise a selection marker located in tandem with the claimed R6Kori sequence.
The instant claimed sequences (i.e., SEQ ID NOs: 35, 60, 62, and 71) are drawn to point (ii) of claim 1 of ‘511. Thus, SEQ ID NOs: 35, 60, 62, and 71 are drawn to a “second portion comprising a nucleic acid sequence consisting essentially of a first adeno-associated virus (AAV) inverted repeat sequence, an R6Kγ bacterial origin of replication (oriR6Kγ) sequence, and a second AAV inverted repeat sequence”, i.e., allowed subject matter.
Thus, after a thorough sequence search and a thorough search of the related applications and the prior art, the claimed subject matter of claims 36-43 is directed to allowable subject matter.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE R SMALL whose telephone number is (703)756-4783. The examiner can normally be reached Monday - Friday 8:30am-4pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chris Babic can be reached on 571-272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KATHERINE R SMALL/Examiner, Art Unit 1633
/EVELYN Y PYLA/Primary Examiner, Art Unit 1633